Mologen AG To Present Poster At ASCO Annual Meeting
Berlin, May 27, 2015 – The biotechnology company MOLOGEN AG will present a poster on the phase II clinical trial “IMPACT” with the cancer immunotherapy MGN1703 at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (May 29-June 2, 2015). The poster will mainly outline updated data on a subgroup of patients with long-term progression-free survival (PFS) from the IMPACT trial in colorectal cancer. The evaluation performed in April 2015 reported a PFS ranging from 44 to 51 months for these patients. In the IMPACT study patients with prior response to induction therapy appeared to benefit most from the treatment with MGN1703. The study design of the currently ongoing pivotal trial IMPALA is based on the findings from the IMPACT trial.
The poster will be featured on May 30, from 08.00 am to 11.30 am at the general poster session “Developmental Therapeutics—Immunotherapy”.
Abstract details:
Abstract Number: 3049
Title: “A subgroup with improved overall survival from the phase II IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703”
Abstract Session: May 30, 2015 from 8.00 am – 11.30 am.
For more information please visit ASCO’s website: http://am.asco.org/
For more information on the IMPACT and IMPALA trials please visit www.clinicaltrials.gov.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy) was a phase II, randomized, placebo-controlled, double-blind, multicenter clinical study aiming to determine the efficacy of MGN1703 as switch maintenance therapy following first-line chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer.
Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data.
About MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN. It broadly activates the immune system. This activation can be utilized to enable the immune system to better recognize and combat cancer cells. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immunotherapies and DNA vaccines against infectious diseases.
The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.
With unique, patented technologies and innovative products, MOLOGEN is pioneering immunotherapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Help employers find you! Check out all the jobs and post your resume.
The poster will be featured on May 30, from 08.00 am to 11.30 am at the general poster session “Developmental Therapeutics—Immunotherapy”.
Abstract details:
Abstract Number: 3049
Title: “A subgroup with improved overall survival from the phase II IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703”
Abstract Session: May 30, 2015 from 8.00 am – 11.30 am.
For more information please visit ASCO’s website: http://am.asco.org/
For more information on the IMPACT and IMPALA trials please visit www.clinicaltrials.gov.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy) was a phase II, randomized, placebo-controlled, double-blind, multicenter clinical study aiming to determine the efficacy of MGN1703 as switch maintenance therapy following first-line chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer.
Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data.
About MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN. It broadly activates the immune system. This activation can be utilized to enable the immune system to better recognize and combat cancer cells. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer.
MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immunotherapies and DNA vaccines against infectious diseases.
The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.
With unique, patented technologies and innovative products, MOLOGEN is pioneering immunotherapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com
Help employers find you! Check out all the jobs and post your resume.